pooling the 12 week arms (since ABBV and presumably GILD both have strong data for 12 week therapy in null responders and cirrhotics) yields a virologic failure rate of 6% (7/115). Adding in what should be about a 1.5-2% non-virologic failure rate c/w GILD and ABBV's large phase 3s give you a 92-93% SVR in this difficult to tx pt group. ABBV had a 92% SVR in cirrhotics on ITT basis and 95% in null responders. So MRK does seem to be within stiking range in terms of SVRs
Market Data 
Markets 
AI
